research Dihydrotestosterone Induces p27 Degradation via Direct Binding with SKP2 in Ovarian and Breast Cancer
Dihydrotestosterone causes p27 protein breakdown in ovarian and breast cancer cells by binding with SKP2.
Search
for
Sort by
Research
60-90 / 186 results 
research Recent Developments in Luteolin-Loaded Nanoformulations for Enhanced Anti-Carcinogenic Activities: Insights from In Vitro and In Vivo Studies
Nanoformulations improve luteolin's effectiveness as a cancer treatment.
research Safety and Patient-Reported Outcomes in Patients With Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer Treated With CDK4/6 Inhibitors in China: A Cross-Sectional Study
Dalpiciclib is the safest and most satisfying CDK4/6 inhibitor for advanced breast cancer patients in China.
research Ductal Breast Cancer in a Male Patient
An 86-year-old man with prostate cancer was diagnosed with a rare, low-grade breast cancer and underwent surgery but declined additional hormone therapy.
research Detection of Metastatic Breast Carcinoma Cells in a Bone Marrow Sample by Flow Cytometry: Case Report
Flow cytometry was effective in diagnosing metastatic breast cancer in a bone marrow sample.
research Understanding Key Symptoms, Side Effects, and Impacts of HR+/HER2- Advanced Breast Cancer: Qualitative Study Findings
Patients with HR+/HER2- advanced breast cancer commonly experience fatigue, hair loss, and pain, which significantly affect daily activities.
research Safety of 5α-Reductase Inhibitors and Spironolactone in Breast Cancer Patients Receiving Endocrine Therapies
The medications 5α-reductase inhibitors and spironolactone are generally safe for breast cancer patients on endocrine therapies and do not significantly increase breast cancer risk.
research Cyclin-Dependent Kinase 4/6 Inhibitors and Dermatologic Adverse Events: Results from the EADV Task Force Dermatology for Cancer Patients International Study
Skin side effects from CDK4/6 inhibitors in breast cancer patients are generally mild and treatable, allowing most patients to continue treatment.
research Androgen Receptor in Human Health: A Potential Therapeutic Target
The Androgen Receptor could be a target for treating diseases like cancer, but more research is needed to confirm the effectiveness of potential treatments.
research Supportive Oncodermatology: Addressing Dermatologic Adverse Events Associated with Oncologic Therapies
Cancer survivors often experience worse skin problems from treatment than expected, and working with dermatologists could help improve their condition.
research Prophylaxis and Management of Skin Toxicities
Preventive measures and effective management are crucial for reducing skin side effects in cancer treatment.
research Giant Morpheaform Basal Cell Carcinoma Mimicking Scarring Alopecia: Exception Prone to Neglect
A rare type of skin cancer on the scalp can be mistaken for hair loss, causing delayed diagnosis and severe damage.
research Enriching Proteolysis Targeting Chimeras with a Second Modality: When Two Are Better Than One
Adding a second method to PROTACs could improve cancer treatment.
research Redefining Hormone Resistance in Prostate Cancer
The conclusion suggests that prostate cancer should be classified by castration status and that new therapies targeting androgen receptor signaling show promise.
research Cutaneous Toxicities of New Targeted Cancer Therapies: Must Know for Diagnosis, Management, and Patient-Proxy Empowerment
New targeted cancer drugs can cause skin side effects, and managing them requires patient education and timely care.
research Cutaneous Adverse Effects of Targeted Therapies
Targeted cancer therapies often cause serious skin problems that need careful management.
research The Management of EGFR Inhibitor Adverse Events: A Case Series and Treatment Paradigm
Skin side effects from EGFR inhibitor cancer treatment can be managed effectively, often without stopping the medication.
research Toxic Side Effects of Targeted Therapies and Immunotherapies Affecting the Skin, Oral Mucosa, Hair, and Nails
Cancer treatments targeting specific cells and the immune system can cause skin, mouth, hair, and nail problems, affecting patients' quality of life and treatment adherence.
research Targeting the Wnt Pathways for Therapies
Blocking the Wnt pathway could lead to new treatments for cancer and tissue repair but requires careful development to avoid side effects.
research Advances in the Management of Cutaneous Toxicities of Targeted Therapies
Targeted cancer therapies often cause skin problems that need careful management to improve patient quality of life and treatment success.
research Dermatologic Side Effects of Systemic Targeted Anticancer Therapy
Cancer treatments targeting specific cells often cause skin, hair, and nail problems, affecting patients' lives and requiring careful management.
research EGFR Inhibitors and Cutaneous Complications: A Practical Approach to Management
The document provides advice on how to recognize and treat skin-related side effects of cancer drugs known as EGFR inhibitors.
research Improving Selective Androgen Receptor Modulator Discovery and Preclinical Evaluation
We need better ways to test and understand SARMs to make safer and more effective treatments.
research Aging and Immortality: Quasi-Programmed Senescence and Its Pharmacologic Inhibition
The conclusion is that using drugs to block the TOR pathway might slow aging and prevent age-related diseases.
research Cancer-Related Alopecia: From Etiologies to Global Management
The document concludes that understanding and managing hair loss in cancer patients is important, and more research is needed for better treatments.
research The Ophthalmological Complications of Targeted Agents in Cancer Therapy: What Do We Need to Know as Ophthalmologists?
Cancer treatments can cause various eye problems, so eye doctors should know how to diagnose and treat these early.
research A Systematic Review on Drug Re-Profiling/Re-Purposing
The document concludes that drug repurposing, which is reusing known medicines for new illnesses, can provide faster, cheaper treatment options for various serious diseases, including cancer, COVID-19, and rare diseases.
research Understanding, Recognizing, and Managing Toxicities of Targeted Anticancer Therapies
Targeted anticancer therapies can cause severe side effects similar to traditional chemotherapy, but with different types.
research Chemotherapy-Induced Alopecia
Chemotherapy often causes hair loss, which usually grows back within 3 to 6 months, but there's no effective treatment to prevent it.
research Differential Expression Analysis of Balding and Nonbalding Dermal Papilla MicroRNAs in Male Pattern Baldness Using a MicroRNA Amplification Profiling Method
Certain microRNAs are more common in balding areas and might be involved in male pattern baldness.